Neurogene (NGNE) Projected to Post Earnings on Friday

Neurogene (NASDAQ:NGNE) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of ($1.05) per share for the quarter.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.05. The business had revenue of $0.93 million during the quarter. On average, analysts expect Neurogene to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Neurogene Trading Up 6.2 %

Shares of NGNE opened at $13.86 on Thursday. Neurogene has a 12-month low of $6.88 and a 12-month high of $74.49. The company has a market capitalization of $197.67 million, a PE ratio of -3.25 and a beta of 1.56. The business’s 50 day moving average is $13.54 and its 200 day moving average is $22.18.

Insider Buying and Selling at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the transaction, the chief financial officer now directly owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. The trade was a 5.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.92% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. HC Wainwright lowered their target price on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. William Blair reissued an “outperform” rating on shares of Neurogene in a research note on Tuesday, March 25th. BMO Capital Markets reduced their price objective on Neurogene from $45.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 14th. Finally, Robert W. Baird set a $38.00 target price on Neurogene in a research report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Neurogene presently has an average rating of “Buy” and a consensus target price of $47.20.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.